Key result
BNP to NT-proBNP conversion formulas offer practical clinical utility but require careful consideration of individual patient factors, pathologies, and assay differences.
Clinical application of BNP to NT-proBNP conversion formulas must account for biological variables, assay differences, and patient-specific factors.
potential of NT-proBNP, which is less susceptible to ARNI, and to measure it more frequently, requiring the development of a platform that enables the comparison and evaluation of previously obtained data or data obtained from other institutions.In cardiomyocytes, mechanostress, ischemia, and various cytokines induce BNP gene expression.ProBNP, the trans-B -type natriuretic peptide (BNP) and N-terminal-pro BNP (NT-proBNP) are established biomarkers of heart failure (HF). 1 Previously, because of limitations in both assay development and the Japanese health insurance system, many institutions measured only BNP and not NT-proBNP.In the recent global HF guidelines, angiotensin-receptor neprilysin inhibitor (ARNI) was placed as one of the key drugs for the treatment of HF, 1 and since then the focus on the natriuretic peptide system has increased.This has led many facilities to reevaluate the
No takes yet. Share an insight, caveat, or question.
Okumura et al. (2022) conducted an editorial in Heart failure. BNP to NT-proBNP conversion formulas was evaluated. BNP to NT-proBNP conversion formulas offer practical clinical utility but require careful consideration of individual patient factors, pathologies, and assay differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: